A $90 Medicare Rebate Is Going Out Now. Here’s Who Actually Gets It
A new $90 Medicare payment is arriving for millions of beneficiaries this October, but it is not a universal Medicare bonus. The one-time rebate is aimed at a specific group of people enrolled in Original Medicare Part B, and beneficiaries in Medicare Advantage are excluded. Income also matters, because people paying Medicare’s high-income surcharge and those receiving Medicaid help with their Part B premium generally do not qualify.
CMS says roughly 20.8 million people are eligible for the payment, with most receiving $90 by direct deposit on or around Oct. 8, 2026. Others will receive a Treasury check later in October, and beneficiaries do not need to apply separately if they qualify. The payment comes from the Medicare Improvement Fund and is intended to offset part of the cost of Medicare Part B.
Who Qualifies for the $90 Medicare Rebate?
Eligibility begins with the type of Medicare coverage someone has. Beneficiaries must be enrolled in Original Medicare Part B and living in the United States, while people enrolled in Medicare Advantage are not eligible for this particular payment. CMS also excludes beneficiaries whose Part B premium is being assisted through Medicaid and those who pay an Income-Related Monthly Adjustment Amount, commonly known as IRMAA.
That makes the rebate narrower than a general payment to everyone on Medicare. Someone with Original Medicare, a Medigap plan and Part D can potentially qualify because Medigap does not replace Original Medicare. Someone receiving Part A and Part B through a Medicare Advantage plan, however, will not receive the $90 rebate even if that plan has no monthly premium.
Beneficiaries who are unsure can call 1-800-MEDICARE to verify eligibility. CMS says people who want to check the status of an expected payment can contact Social Security beginning Oct. 15 if the deposit or check has not arrived.
Higher-Income Beneficiaries Are Excluded
The income rule is another area where misinformation can spread quickly. The Medicare surcharge is called IRMAA, and in 2026 it begins when modified adjusted gross income exceeds $109,000 for an individual or $218,000 for a married couple filing jointly. Those thresholds are based generally on income reported two years earlier, so 2026 Medicare premiums typically reflect 2024 tax-return information.
Beneficiaries above those thresholds pay additional premiums for Part B and, if applicable, Part D. Because the $90 rebate is restricted to people who are not paying IRMAA, a higher-income beneficiary enrolled in Original Medicare can still be excluded even though the basic Medicare coverage is otherwise the same.
This is an important correction to claims that the cutoff begins around $19,000 for individuals. That figure is nowhere close to the 2026 IRMAA threshold and could create unnecessary confusion for retirees trying to determine whether a payment is coming.
The Part B Premium Did Not Jump to $290
Another figure circulating with the rebate is that the Medicare Part B premium supposedly increased from $185 in 2025 to about $290 in 2026. That is incorrect for the standard premium.
The standard Part B premium increased from $185 per month in 2025 to $202.90 in 2026, a monthly increase of $17.90. The annual Part B deductible also rose from $257 to $283. CMS attributes the premium increase primarily to expected medical price changes and higher utilization.
The $90 rebate therefore offsets roughly five months of that $17.90 monthly increase, but it does not reduce the official Part B premium itself. Beneficiaries will continue paying their normal premium, while eligible recipients receive the rebate separately.
The Medicare Improvement Fund Is Not New
The money comes from the Medicare Improvement Fund, which was created by Congress in 2008. The fund was established to finance improvements to Original Medicare Parts A and B, although Congress has redirected money from it numerous times over the years to offset other federal health spending.
The Trump administration chose to use part of the fund for the one-time $90 Part B rebate in 2026. Whatever the political debate around the decision, beneficiaries should treat the payment as a one-time rebate rather than assume it will automatically appear again next year.
There is currently no basis for budgeting around another $90 payment in 2027. Retirement and Medicare planning should continue using the actual premium and benefit rules rather than assuming temporary rebates will become permanent.
Medicare Advantage Members Don’t Get the Rebate
The exclusion of Medicare Advantage beneficiaries may be particularly confusing because Medicare Advantage members still generally have Part B and continue paying the Part B premium. Their benefits, however, are administered through private Medicare Advantage plans rather than through Original Medicare’s fee-for-service system.
CMS specifically restricts the Medicare Improvement Fund rebate to eligible beneficiaries in Original Medicare Part B. That means a retiree should not switch Medicare coverage simply to chase a one-time $90 payment, especially because Medicare Advantage and Original Medicare involve much larger differences in provider networks, supplemental benefits and potential out-of-pocket costs.
A $90 rebate is useful, but it should not influence a decision involving thousands of dollars in annual health-care exposure. The more important question remains whether a beneficiary’s doctors, medications, hospitals and financial preferences fit the coverage chosen for the coming year.
Part D Is Changing Again for 2027
Prescription drug coverage is also entering another transition. The temporary Part D Premium Stabilization Demonstration that helped moderate standalone drug-plan premium changes in 2025 and 2026 is ending for 2027. CMS says the program is being allowed to expire because insurers now have more experience pricing the redesigned Part D benefit.
Despite the end of that additional stabilization program, CMS projects that the average standalone Part D premium will increase by less than $1 per month for 2027. Medicare Advantage plans that include drug coverage are expected to see the average drug-plan portion of premiums decline substantially, although individual premiums can vary considerably by plan and location.
That makes the Annual Notice of Change particularly important this fall. A beneficiary should check not only the monthly premium but also drug tiers, formularies, deductibles and preferred pharmacies because an inexpensive premium can be overwhelmed by higher prescription costs.
A New $50 GLP-1 Program Is Already Available
Another major Medicare development is the Medicare GLP-1 Bridge, which began July 1, 2026. Eligible beneficiaries with Medicare Part D coverage can receive certain weight-management GLP-1 drugs for a $50 monthly copay through the temporary program, which CMS has extended through Dec. 31, 2027.
Unlike the $90 rebate, the GLP-1 Bridge is not restricted to Original Medicare beneficiaries. Eligible people can participate through standalone Part D coverage or many Medicare Advantage plans that include prescription drugs, as well as qualifying Special Needs Plans and certain employer or union plans.
The program operates outside the normal Part D payment structure. The $50 copay does not count toward the Part D deductible or the beneficiary’s Part D out-of-pocket spending total, and drug manufacturers’ coupons cannot be stacked on top of the program.
Not Everyone Taking a GLP-1 Qualifies
The GLP-1 Bridge has detailed clinical requirements. A beneficiary can qualify with a BMI of at least 35, or a BMI of at least 30 combined with conditions such as certain heart failure, uncontrolled hypertension or stage 3a or higher chronic kidney disease. Someone with a BMI of at least 27 may qualify if they also have prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.
The program is specifically designed for weight management. People with type 2 diabetes, moderate-to-severe sleep apnea or certain fatty-liver disease conditions are excluded from the bridge because those conditions may qualify for GLP-1 coverage through the regular Part D benefit. A doctor must submit a prior-authorization request confirming that the beneficiary meets the program’s criteria.
Currently covered products include certain versions of Wegovy, Zepbound and Foundayo. Beneficiaries should not assume that every GLP-1 medication or every formulation is included simply because it belongs to the same drug class.
Don’t Let the $90 Distract From Open Enrollment
The rebate is receiving attention because it is immediate and easy to understand, but the bigger Medicare financial decision arrives during Open Enrollment. Medicare beneficiaries can compare 2027 Medicare Advantage and Part D options from Oct. 15 through Dec. 7, with selected coverage generally beginning Jan. 1.
A $90 payment is small compared with the difference between two plans when prescription costs, hospital copayments or provider networks are taken into account. Someone who receives the rebate should still review the Annual Notice of Change and compare 2027 coverage rather than automatically allowing the current plan to renew.
The same applies to people who do not receive the rebate. Being excluded because of Medicare Advantage enrollment or IRMAA does not indicate anything about whether the existing Medicare strategy is good or bad; it only means the beneficiary does not meet the eligibility rules for this particular payment.
The Bottom Line
The $90 Medicare rebate is real, but it is not a payment for everyone on Medicare. It is a one-time October 2026 rebate for eligible Original Medicare Part B beneficiaries who live in the United States, do not receive Medicaid assistance with the premium and do not pay IRMAA. Medicare Advantage beneficiaries are specifically excluded.
At the same time, beneficiaries should keep the payment in perspective. The standard 2026 Part B premium is $202.90, Part D plans are changing again for 2027, and a new GLP-1 program can provide certain eligible beneficiaries with substantially more financial value than the rebate itself.
Medicare increasingly contains one-time programs, demonstrations and plan-specific changes that can make simple headlines misleading. The safest approach is to verify eligibility through Medicare, review the actual coverage documents and make decisions based on the total annual cost of health care rather than any single rebate or benefit.
